SeraCare Announces the Expansion of Their Proprietary AccuPlex™ Technology Product Portfolio with the Launch of the AccuSpan™ HCV RNA Linearity Panel

MILFORD, Mass., July 25, 2018 /PRNewswire/ -- SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, is announcing the launch of their all-new AccuSpan™ HCV RNA Linearity Panel – the latest product built with their proprietary AccuPlex™ recombinant technology.  This eight-member panel, qualified against WHO standards, is made from serial dilutions of high-titer recombinant hepatitis C virus (genotype 1b) with established reactivity for HCV RNA, and one negative member. Researchers, diagnostic manufacturers, and clinical laboratories can use it to develop, evaluate, and validate HCV molecular test methods.  The AccuSpan HCV RNA Linearity Panel is ideal for monitoring HCV RNA recovery at defined intervals, identifying consistency over a linear range, assessing kit lot-to-lot variability, performing linearity studies, or whenever there are indications of possible assay deterioration.

SeraCare's exclusive AccuPlex technology enables the safest, most patient-like full-process molecular controls available on the market. Unlike other technologies that package viral RNA into a bacteriophage, AccuPlex recombinants closely resemble the wild-type mammalian pathogenic virus. This enables the release of the viral genome at a similar rate to the wild-type virus during the nucleic acid sample preparation process. AccuPlex recombinant material is stable, replication-deficient, non-infectious, and mimics a real patient sample throughout the diagnostic workflow, serving as a true full-process control for molecular assays.

SeraCare will be on hand in booth #1367 at the 2018 AACC Scientific Meeting in Chicago, IL, from July 29 to August 2 to discuss AccuPlex recombinant technology as well as their comprehensive portfolio of quality controls and validation panels to support in vitro diagnostic development and end-user assay performance. The featured scientific poster on the utilization of AccuPlex technology, titled Development of a Comprehensive set of Zika Virus Materials for Validation and Evaluation of Performance of Serological and Molecular Assays, will be presented on August 1^st at 12:30 pm. SeraCare will also present posters on reference materials for NGS-based myeloid cancer assays, and PD-L1 expression by IHC.  

Learn more about the innovative AccuPlex technology behind our newest products such as AccuSpan™ HCV RNA Linearity Panel at https://www.seracare.com/resources-and-education/accuplex-recombinant-virus-materials/

About SeraCare Life Sciences, Inc.

SeraCare enables the promise of precision medicine by advancing the understanding of disease and providing assurance of the diagnostic result. Our innovative tools and technologies not only provide assurance of the safe, effective, and accurate performance of diagnostic assays but also establish a framework for regulating, compiling, and interpreting data from precision diagnostics. Our portfolio includes a broad range of products such as quality control technologies, disease-state specimens and tissues for research and development, processed biological materials, and immunoassay reagents. For more information, please visit www.seracare.com and follow SeraCare on Twitter (@SeraCare).

Company Contact:
Heather DelCarpini
SeraCare Life Sciences, Inc.
508.244.6429
[email protected]
www.seracare.com

SOURCE SeraCare Life Sciences

Related Links

http://www.seracare.com